Barrx 90

Manufactured by Medtronic

Sourced in United States

The Barrx 90 is a medical device designed for use in endoscopic procedures. It is a radio frequency ablation system that delivers controlled, uniform thermal energy to targeted tissue. The Barrx 90 is intended to facilitate the removal or destruction of abnormal tissue.

Automatically generated - may contain errors

Lab products found in correlation

Barxx360 system, by Medtronic (1 mentions) Cf hq190l, by Olympus (1 mentions)

4 protocols using barrx 90

Endoscopic Resection and Ablation for ESCN

Check if the same lab product or an alternative is used in the 5 most similar protocols

Experienced endoscopists in CICAMS conducted all endoscopic procedures. All preoperative ESCN lesions with HGIN or worse histologic grade in biopsy specimens that met the Japan Esophageal Society guideline or the European Society of Gastrointestinal Endoscopy (ESGE) guidelines received ER (ESD or EMR) (14 (link), 19 (link)). The ESD/EMR procedures included Lugol’s iodine staining, marking, submucosal injection, submucosal dissection/mucosal incision, and wound treatment (7 (link), 8 (link)). The ER specimens were examined by at least two experienced pathologists based on the Japanese Classification of Esophageal Cancer (14 (link), 20 (link), 21 (link)).
However, the multiple LVLs containing LGIN outside the resected lesion were radiofrequency ablated through the Barrx™ Ablation System (Medtronic, Sunnyvale, CA, USA). The multiple LVLs of which the range was more than 3/4 of the circumference were treated with circumferential RFA regimens (BARXX³⁶⁰ system), while the scattered multiple LVLs were dealt with focal RFA (BARRX⁹⁰, 3 × 12 J/cm²; Medtronic). The locations of all lesions and all treatment area (TA) (both ER and RFA) were determined by their distance from the incisor and their clock position on the circumferential esophagus. All data were recorded in the endoscopic reports.

Chen Z., Dou L., Liu Y., Zhang Y., He S., Xue L, & Wang G. (2021). Combination of Endoscopic Resection and Radiofrequency Ablation for the Treatment of Esophageal Squamous Cell Neoplasia With Multiple Lugol-Voiding Lesions. Frontiers in Oncology, 11, 786015.

+ Open protocol

+ Expand

Optimized Ablation Paddle Design for OCT-Guided RFA

Check if the same lab product or an alternative is used in the 5 most similar protocols

A commercial RFA instrument with a focal RFA catheter (Barrx Flex, Model 90-9000 and Barrx 90, Medtronic, Minneapolis) was used in this study. The instrument allowed adjustment of the RF energy settings between 12 and

15 J / {cm}^{2}

(power density:

40 W / {cm}^{2}

, frequency: 460 kHz, duration:

\sim 0.3 s

) for the Barrx 90 catheter. The catheter ablation paddle was

13 \times 20 {mm}^{2}

and covered by an electrode array of 24 electrodes. Each electrode was

250 - μ m

wide with a separation of

250 μ m

from the adjacent electrodes. To improve light transmission and reduce aberration through the ablation paddle, a small region (

\sim 4 \times 4 {mm}^{2}

) on the back of the paddle was machined to thin supporting plastic material without affecting the electrodes' integrity. The modified ablation paddle is shown in the lower right inset in Fig. 1, where the region (red arrow) allows OCT imaging during RFA application.

Lee H.C., Ahsen O.O., Liu J.J., Tsai T.H., Huang Q., Mashimo H, & Fujimoto J.G. (2017). Assessment of the radiofrequency ablation dynamics of esophageal tissue with optical coherence tomography. Journal of Biomedical Optics, 22(7), 076001.

+ Open protocol

+ Expand

Optical Coherence Tomography of Radiofrequency Ablation for Chronic Radiation Proctitis

Check if the same lab product or an alternative is used in the 5 most similar protocols

This study was conducted at the Veteran Affairs Boston Healthcare System. Two patients with normal rectum and 8 patients referred for, or undergoing endoscopic treatment with RFA for CRP were enrolled in the study between October 2013 and November 2016 (n = 10). Five of the CRP patients were RFA-naïve at the baseline visit (time of initial OCT imaging), while 3 patients had previous RFA treatments. Five of the CRP patients imaged at the baseline visit were also imaged at RFA-follow-up visits within the study period, yielding a total of 15 OCT/colonoscopy visits 2 normal patients, 5 RFA-naïve patients, 8 RFA-follow-up visits). OCT imaging was performed during scheduled colonoscopy visits immediately before the colonoscopy procedure. Standard rectal examination with the colonoscope was conducted subsequent to OCT imaging. RFA was performed in patients with active rectal bleeding and/or based on endoscopic indication. A focal ablation catheter (Barrx 90, Medtronic, MN, United States) attached to the colonoscope (CF-HQ190L or CF-2T160, Olympus, Japan) typically in the six o’clock position and applied to the rectal mucosa with the endoscope retroflexed, as previously described[16 (link)]. Patient charts were reviewed to obtain information about rectal bleeding status and hemoglobin concentrations before and after the colonoscopy visits.

Ahsen O.O., Liang K., Lee H.C., Wang Z., Fujimoto J.G, & Mashimo H. (2019). Assessment of chronic radiation proctopathy and radiofrequency ablation treatment follow-up with optical coherence tomography angiography: A pilot study. World Journal of Gastroenterology, 25(16), 1997-2009.

+ Open protocol

+ Expand

Standardized Rescue RFA for Persistent BE

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patients with persisting BE after completion of the study underwent additional treatment with focal RFA (Barrx 90, Covidien/ Medtronic, Minneapolis, USA; dose 3 × 12 J/cm 2 without cleaning in between applications) until CE-IM. These treatments were standardized, with ablation of all visible BE and the gastroesophageal junction in 3 -4-month intervals. Argon plasma coagulation was used as rescue treatment for persisting small (< 5 mm) BE islands after RFA. Although these procedures were not part of the formal study protocol and were performed in the context of regular clinical care, the treatment strategy was in line with national BE guidelines [18] and was thus standardized. We retrospectively collected final outcomes for all patients (number of additional treatments, CE-IM rates, and adverse events). These outcomes are reported at the end of the results section to provide complete data on efficacy and safety after additional ablation.

van Munster S.N., Overwater A., Raicu M.G.M., Seldenrijk K.C.A., Nagengast W.B., Schoon E.J., Bergman J.J.G.H.M, & Weusten B.L.A.M. (2020). A novel cryoballoon ablation system for eradication of dysplastic Barrett's esophagus: a first-in-human feasibility study. Endoscopy, 52(3).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!